Core Insights - Compass Pathways reported its fourth quarter and full-year 2025 financial results, highlighting advancements in its COMP360 treatment for mental health conditions, particularly treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD) [1][3][4] Business Highlights - COMP360 is positioned as a potential first classic psychedelic treatment approved by the FDA, demonstrating rapid onset of action and durability in TRD patients, with effects lasting at least six months after one or two doses [3][4] - The company is preparing for an FDA meeting to confirm its New Drug Application (NDA) submission strategy, including a rolling submission and review, with expectations to complete the NDA submission in Q4 2026 [4][6] - A Phase 2b/3 trial for PTSD has been initiated following FDA acceptance of the Investigational New Drug (IND) application, reinforcing the company's commitment to innovative treatments [4][7] Financial Highlights - Research and development expenses for Q4 2025 were $29.9 million, a decrease from $32.1 million in Q4 2024, attributed to reduced staffing levels [6][12] - The net loss for Q4 2025 was $93.9 million, compared to $43.3 million in Q4 2024, primarily due to a non-cash loss on fair value adjustment related to warrant liabilities [12][22] - Cash and cash equivalents stood at $149.6 million as of December 31, 2025, down from $165.1 million in 2024, with a cash position expected to fund operations into 2028 [12][8] Clinical Development - COMP360 has shown a significant clinical profile in TRD, with a 25% reduction in depressive symptoms observed as early as the day after administration in pivotal trials [7][4] - The treatment is expected to fit seamlessly into existing healthcare infrastructures, with over 7,300 centers prepared for its launch [7][4] - The company anticipates that COMP360 will offer a patient-friendly dosing schedule and has the potential to become a blockbuster treatment in the mental health space [5][7]

Financial Data and Key Metrics Changes - Total revenue in Q4 2025 was $41.8 million, an increase of 86% compared to $22.5 million in Q4 2024, primarily driven by the inclusion of Greenbrook operations following the acquisition [17] - Adjusted pro forma revenue growth for Q4 was 23% year-over-year [17] - Gross margin was 52% in Q4 2025, down from 66% in the prior year, due to the inclusion of Greenbrook's lower-margin clinic business [19] - Net loss for Q4 2025 was $7.2 million, or $0.10 per share, compared to a net loss of $12.7 million, or $0.34 per share in the prior year [20] Business Line Data and Key Metrics Changes - Total revenue from the NeuroStar business was $18.3 million in Q4 2025, representing a 9% increase on a pro forma basis [17] - U.S. NeuroStar system revenue was $4.4 million, a 15% year-over-year increase, with 49 systems shipped in the quarter [18] - U.S. treatment session revenue was $12.4 million, with a 6% increase on a pro forma basis compared to the prior year [18] - Clinic revenue for Q4 was $23.5 million, a 37% increase on an adjusted pro forma basis, driven by growth in treatments across both NeuroStar TMS and Spravato [18] Market Data and Key Metrics Changes - The referring provider network added 430 new providers in Q4, a 25% increase year-over-year, contributing to over 1,300 new referrers added across 2025 [7] - Total treatment volume increased by 18% year-over-year in Q4 [8] - TRICARE West expanded coverage for TMS therapy to include adolescents aged 15 and older, effective across 26 states [12] Company Strategy and Development Direction - The company aims to leverage its integrated model to drive growth through expanding how NeuroStar TMS systems are brought to market and addressing the unmet need for treatment-resistant depression (TRD) [25][26] - Collaboration with Compass Pathways on COMP360 psilocybin is seen as a potential transformational treatment for TRD, with plans for commercial launch upon FDA approval [27][29] - The company is focused on operational efficiencies and expects to reduce operating expenses while driving revenue growth [22][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to achieve positive operating cash flow and improve cash conversion through operational efficiencies [20][21] - The company anticipates strong revenue performance in 2026, with guidance for total revenue between $160 million and $166 million, representing over 9% growth versus 2025 [21][22] - Management acknowledged seasonality impacts on revenue, particularly in Q1, and noted weather-related challenges affecting patient access [51][54] Other Important Information - The company appointed Dan Reuvers as the new President and CEO, effective March 23, 2026 [5] - The company achieved positive operating cash flow in Q4 2025, marking a significant milestone [6] Q&A Session Summary Question: Insights on CID investigation in Florida and Michigan - Management confirmed ongoing cooperation with the U.S. Attorney's Office regarding documentation for billing practices prior to the Greenbrook acquisition [35] Question: Differences in patient monitoring for COMP360 - The Chief Technology Officer explained that COMP360 would be administered under a REMS protocol similar to Spravato, with durable treatment effects after one or two doses [38] Question: Cash position after debt payment - Management clarified that the $5 million payment to Perceptive came from non-restricted cash, leaving a comfortable cash balance for operations [41][42] Question: Guidance on clinic growth and Spravato - Management indicated that the majority of growth in the clinic business would come from volume, with Spravato expected to represent a growing share of treatment volume [46][47] Question: Integration of COMP360 into existing infrastructure - Management stated that the existing infrastructure and staff at Greenbrook clinics are well-prepared to administer COMP360 treatments [65]

Financial Data and Key Metrics Changes - Total revenue in Q4 2025 was $41.8 million, an increase of 86% compared to $22.5 million in Q4 2024, primarily driven by the inclusion of Greenbrook operations following the acquisition [17] - Adjusted pro forma revenue growth for Q4 was 23% year-over-year [17] - Net loss for Q4 2025 was $7.2 million, or $0.10 per share, compared to a net loss of $12.7 million, or $0.34 per share in the prior year [20] - EBITDA for Q4 2025 was negative $4.3 million, an improvement from negative $11 million in the prior year [20] - Cash provided by operations in Q4 was positive $0.9 million, marking a significant improvement from negative cash flow earlier in the year [21] Business Line Data and Key Metrics Changes - NeuroStar business revenue, including system and treatment session revenue, was $18.3 million in Q4 2025, representing a 9% increase on a pro forma basis [17] - U.S. NeuroStar system revenue was $4.4 million, a 15% year-over-year increase, with 49 systems shipped in the quarter [18] - U.S. treatment session revenue was $12.4 million, with a pro forma increase of 6% compared to the prior year [18] - Clinic revenue for Q4 was $23.5 million, a 37% increase on an adjusted pro forma basis, driven by growth in treatments across both NeuroStar TMS and Spravato [18] Market Data and Key Metrics Changes - The referring provider network added 430 new providers in Q4, a 25% increase year-over-year, contributing to over 1,300 new referrers added across 2025 [7] - Total treatment volume increased by 18% year-over-year in Q4 [9] - The expansion of TRICARE West coverage for TMS therapy to include adolescents aged 15 and older is a significant development for military families [13] Company Strategy and Development Direction - The company aims to leverage its integrated model to drive growth through expanding how NeuroStar TMS systems are brought to market and addressing the unmet need for treatment-resistant depression (TRD) [26][28] - Collaboration with Compass Pathways on COMP360 psilocybin is seen as a potential transformational treatment for TRD, with plans for commercial launch upon FDA approval [28][29] - The company is focused on operational efficiency and expects to reduce operating expenses to less than $100 million by Q4 2026 [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to drive revenue growth and achieve sustainable operating cash flow, with expectations for positive cash flow in the second half of 2026 [25] - The company acknowledges seasonality impacts on revenue, particularly in Q1, and is adapting its strategies accordingly [55][56] - Management highlighted the importance of maintaining strong relationships with primary care physicians and enhancing patient access to treatments [26] Other Important Information - The company appointed Dan Reuvers as the new President and CEO, effective March 23, 2026, indicating a leadership transition [5] - The company has made significant progress in integrating Greenbrook's operations, achieving positive operating cash flow and strengthening its balance sheet [16] Q&A Session Summary Question: Can you provide details on the CID investigation in Florida and Michigan? - Management confirmed that they are cooperating with the U.S. Attorney's Office regarding documentation for billing practices prior to the Greenbrook acquisition [36] Question: What are the profitability and patient monitoring differences for COMP360? - The treatment effect of COMP360 appears durable after one or two doses, and it will be administered under a REMS protocol similar to Spravato [40][42] Question: How did the $5 million payment to Perceptive affect cash position? - The payment did not come from restricted cash, and the company remains comfortable with its cash position despite projected Q1 cash burn [43][44] Question: Can you elaborate on the growth guidance for the clinic and standalone businesses? - Majority of growth in the clinic business is expected to come from volume, with Spravato growth anticipated to be significant in Q1 due to buy-and-bill impacts [50] Question: What are the integration requirements for the Compass collaboration? - The existing infrastructure for Spravato clinics will facilitate the integration of COMP360 treatments, with minimal additional updates needed [68]

Transforming Lives Through NeuroHealth COMPANY PRESENTATION NASDAQ: STIM March 2026 Forward Looking Statements This presentation contains estimates and other statistical data prepared by independent parties and by Neuronetics, Inc. ("Neuronetics" or the "Company") relating to market size and growth and other data about the industry in which the Company operates. These estimates and data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates and data ...

Core Insights - Compass Pathways plc is a biotechnology company focused on mental health innovation, particularly through its investigational treatment COMP360, which has received Breakthrough Therapy designation from the FDA and ILAP designation in the UK for treatment-resistant depression [2][8]. Company Participation in Conferences - Compass Pathways will participate in two investor conferences in December 2025: the 8th Annual Evercore Healthcare Conference on December 2 at 10:00 am ET and the Piper Sandler 37th Annual Healthcare Conference on December 3 at 1:30 pm ET [1][4]. Financial and Business Updates - The company reported its third quarter 2025 financial results, highlighting an acceleration of its commercial launch plans for COMP360 by 9-12 months due to positive discussions with the FDA and completion of COMP006 enrollment [8]. Leadership Changes - Dr. Jeffrey Jonas has been appointed to the Board of Directors of Compass Pathways, bringing over 30 years of experience in pharmaceutical research and development, particularly in neuroscience [9].

Core Insights - Compass Pathways plc is a biotechnology company focused on mental health innovation, particularly through its investigational treatment COMP360, which has received Breakthrough Therapy designation from the FDA and ILAP designation in the UK for treatment-resistant depression [2][8]. Company Participation in Conferences - Compass Pathways will participate in two investor conferences in December 2025: the 8th Annual Evercore Healthcare Conference on December 2, 2025, and the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025 [1][4]. Financial and Business Updates - The company reported its third quarter 2025 financial results, highlighting an acceleration of its commercial launch plans for COMP360 by 9-12 months due to positive discussions with the FDA and completion of COMP006 enrollment [8]. Leadership Changes - Dr. Jeffrey Jonas has been appointed to the Board of Directors of Compass Pathways, bringing over 30 years of experience in pharmaceutical research and development, particularly in neuroscience [9].

Core Viewpoint - Neuronetics, Inc. has entered into a three-year exclusive agreement with Elite DNA Behavioral Health to provide transcranial magnetic stimulation (TMS) devices and patient support services across Elite DNA's 30+ locations, aiming to enhance patient access to advanced mental health treatments [1][2][3] Company Overview - Neuronetics, Inc. focuses on developing products that improve the quality of life for patients with neurohealth disorders and is a leader in neuroscience, particularly in TMS therapy [5][6] - Elite DNA Behavioral Health, founded in 2013, is one of Florida's largest mental health networks, providing accessible mental health care through over 30 locations [4] Partnership Details - The collaboration will utilize Neuronetics' Greenbrook platform to enhance operational and patient-support services for Elite DNA, allowing their team to concentrate on patient experience [2][3] - The partnership aims to operationalize strategic values from Neuronetics' Greenbrook acquisition and serves as a model for future collaborations with other organizations [2] Treatment and Services - NeuroStar Advanced Therapy, a non-invasive TMS treatment, has delivered over 7.6 million treatments and is backed by extensive clinical data, making it the leading TMS treatment for major depressive disorder (MDD) in adults [5][6] - Greenbrook treatment centers also provide SPRAVATO (esketamine) Nasal Spray for treatment-resistant depression, having administered over 1.8 million treatments to more than 55,000 patients [6]

Core Insights - Alexandria Real Estate Equities, Inc. has been awarded the 2025 Charles A. Sanders, MD, Partnership Award by the Foundation for the National Institutes of Health (FNIH) for its leadership in a public-private partnership aimed at advancing precision medicine for depression [1][2] - The initiative, known as Multi-Level Assessment & Phenotyping in Depression (MAP-D), seeks to develop a comprehensive framework for treating major depressive disorder, which affects over 21 million adults in the U.S. annually [2][3] - The MAP-D program aims to create a large depression research dataset, validate new measurement methods, and identify biomarkers to guide treatment decisions [3][4] Company Overview - Alexandria Real Estate Equities, Inc. is a leading life science real estate investment trust (REIT) with a market capitalization of $25.7 billion as of June 30, 2025, and operates in key life science innovation clusters across North America [5][6] - The company specializes in developing collaborative Megacampus ecosystems and has a significant asset base, including 39.7 million rentable square feet (RSF) of operating properties and 4.4 million RSF of properties under construction [5][6] - Alexandria also provides strategic capital to transformative life science companies through its venture capital platform, enhancing its role in the life science ecosystem [6]

Company Leadership Transition - Steven Pfanstiel has been appointed as the new Chief Financial Officer of Neuronetics, effective July 15, 2025, replacing Steve Furlong, who will retire on March 31, 2026 [2][3] - Steve Furlong will continue to serve as Senior Advisor to the CEO during the transition period to ensure operational continuity [2][3] Executive Background - Steven Pfanstiel brings over two decades of healthcare experience, having previously served as CFO and COO at Marinus Pharmaceuticals, where he was instrumental in the launch of the flagship product, Ztalmy [3][4] - Pfanstiel has held senior financial roles at various high-growth healthcare companies, including Lifescan and Optinose, and has experience at Johnson & Johnson across multiple product categories [3][4] Strategic Vision and Growth - Neuronetics aims to expand access to mental health treatments and deliver sustainable growth, leveraging Pfanstiel's expertise in financial leadership and growth strategies [3][4] - The company is focused on integrating Greenbrook operations and achieving positive cash flow in the third quarter of 2025, marking a significant operational milestone [5] Stock Incentives - As part of his employment agreement, Pfanstiel received an inducement grant of 400,000 restricted stock units, with specific vesting schedules tied to his continued employment [4] Company Performance and Market Position - Neuronetics reaffirms its guidance for the second quarter and full year 2025, driven by successful integration efforts and key growth drivers [5] - The company operates Greenbrook TMS treatment centers across the U.S., offering NeuroStar Advanced Therapy, which has delivered over 7.4 million treatments for major depressive disorder (MDD) [6][7]

Financial Data and Key Metrics Changes - As of March 31, 2025, the company reported cash, cash equivalents, and investments totaling $245.5 million, which is expected to fund operations into 2027 [20] - Research and development expenses increased to $23.4 million for Q1 2025, up from $11.7 million in Q1 2024, primarily due to costs associated with the MM120 program [21] - General and administrative expenses decreased to $8.8 million in Q1 2025 from $10.5 million in Q1 2024, attributed mainly to stock-based compensation [21] Business Line Data and Key Metrics Changes - The company is advancing its lead program MM120, targeting generalized anxiety disorder (GAD) and major depressive disorder (MDD) with three pivotal Phase 3 trials actively enrolling [6][20] - The trials, Voyage and Panorama for GAD, and EMERGE for MDD, are designed to assess the efficacy and safety of MM120 ODT [15][19] Market Data and Key Metrics Changes - The company noted a significant unmet need for treatments addressing GAD and MDD, with over 50 million people affected in the U.S. alone [7] - There is a growing awareness and recognition of anxiety disorders, which is expected to benefit clinical research and commercial opportunities for GAD treatments [37] Company Strategy and Development Direction - The company aims to position MM120 ODT as a best-in-class treatment for GAD and MDD, with a clear regulatory strategy and breakthrough therapy designation [7][22] - The new Chief Commercial Officer, Matt Wiley, is expected to lead the commercial strategy during this critical growth phase, leveraging his extensive experience in CNS and psychiatry [9][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing clinical trials and the potential of MM120 ODT to redefine treatment paradigms for GAD and MDD [10][22] - The company anticipates top-line data readouts from the trials in 2026, which will be crucial for future commercialization efforts [20][22] Other Important Information - The company amended its loan agreement to provide greater financial flexibility, allowing access to up to $120 million based on milestone achievements [20] - The company is committed to ensuring participant safety in clinical trials, employing rigorous screening and monitoring processes [50][51] Q&A Session Summary Question: Clarification on the MDG trial and therapeutic effective dose - Management confirmed that the MDD study will not use an intermediate dose, focusing on 100 micrograms versus placebo, and indicated that the same therapeutic dose is expected to be effective in MDD as seen in GAD [24][26] Question: Insights from GAD epidemiology and treatment patterns - Management noted that there is increasing awareness of GAD, which is beneficial for recruitment and clinical trials, and emphasized the importance of understanding treatment patterns [31][37] Question: Engagement with the FDA amid leadership changes - Management reported strong ongoing engagement with the FDA, with no direct impact from recent leadership changes [40][42] Question: Steps to limit enrolling professional patients - The company has implemented strict screening processes to ensure appropriate patient selection and adherence to trial protocols [46][48] Question: Plans for interim data releases in 2025 - Management indicated that there are no plans to release unblinded data this year, focusing instead on executing the studies and ensuring high-quality results [56][58] Question: Market dynamics and commercial planning activities - The company is confident in addressing unmet needs in GAD and MDD, with plans to refine market positioning and messaging in the second half of the year [62][65]